Page last updated: 2024-12-07

sdz nvi-085

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

SDZ NVI-085: a potent anticataplectic agent that may act by stimulating an alpha1-adrenoceptor subtype [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID128503
CHEMBL ID337879
SCHEMBL ID194836
MeSH IDM0200765

Synonyms (16)

Synonym
sdz nvi 085
CHEMBL337879
(4ar,10ar)-6-methoxy-4-methyl-9-methylsulfanyl-2,3,4a,5,10,10a-hexahydrobenzo[g][1,4]benzoxazine
sdz nvi-085
2h-naphth(2,3-b)-1,4-oxazine, 3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-(methylthio)-, (4ar-trans)-
sdz-nvi-085
3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-methylthio-2h-naphth(2,3-b)-1,4-oxazine
104195-17-7
SCHEMBL194836
(-)-(4ar,10ar)-3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-methylthio-2h-naphth[2,3-b]-1,4-oxazine
trans-3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-methylthio-2h-naphth[2,3-b]-1,4-oxazine
SLMAGYSTRWJTMF-TZMCWYRMSA-N ,
DTXSID60146337
sdznvi-085
(4ar,10ar)-6-methoxy-4-methyl-9-(methylthio)-3,4,4a,5,10,10a-hexahydro-2h-naphtho[2,3-b][1,4]oxazine
AKOS040749472
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID171335Alpha adrenergic activity was evaluated as concentration (iv) which increases the arterial pressure by 20 mmHg in the pithed rat1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Design, synthesis, and structure-activity relationships of a new series of alpha-adrenergic agonists: spiro[(1,3-diazacyclopent-1-ene)-5,2'-(1',2',3',4'- tetrahydronaphthalene)].
AID60507Maximal contractile response obtained with the agonist (expressed as a percentage of the maximal contraction to phenylephrine in the dog saphenous vein)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Design, synthesis, and structure-activity relationships of a new series of alpha-adrenergic agonists: spiro[(1,3-diazacyclopent-1-ene)-5,2'-(1',2',3',4'- tetrahydronaphthalene)].
AID59112Effective concentration for the agonist in the isolated blood vessel using in vitro saphenous vein1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Design, synthesis, and structure-activity relationships of a new series of alpha-adrenergic agonists: spiro[(1,3-diazacyclopent-1-ene)-5,2'-(1',2',3',4'- tetrahydronaphthalene)].
AID185553Alpha adrenergic activity was evaluated as maximal pressure response caused by agonist, expressed in mmHg (the maximum obtained with phenylephrine is 150 mmHg).1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Design, synthesis, and structure-activity relationships of a new series of alpha-adrenergic agonists: spiro[(1,3-diazacyclopent-1-ene)-5,2'-(1',2',3',4'- tetrahydronaphthalene)].
AID60506Maximal contractile response obtained with the agonist (expressed as a percentage of the maximal contraction to phenylephrine in the dog femoral artery)1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Design, synthesis, and structure-activity relationships of a new series of alpha-adrenergic agonists: spiro[(1,3-diazacyclopent-1-ene)-5,2'-(1',2',3',4'- tetrahydronaphthalene)].
AID232349Ratio of C20 obtained in the absence or presence of [C20 ( 0.1 mg of prazosin ) / C20 (control)]1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Design, synthesis, and structure-activity relationships of a new series of alpha-adrenergic agonists: spiro[(1,3-diazacyclopent-1-ene)-5,2'-(1',2',3',4'- tetrahydronaphthalene)].
AID232350Ratio of C20 obtained in the absence or presence of [C20 (1 mg of yohimbine.) / C20 (control)]1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Design, synthesis, and structure-activity relationships of a new series of alpha-adrenergic agonists: spiro[(1,3-diazacyclopent-1-ene)-5,2'-(1',2',3',4'- tetrahydronaphthalene)].
AID59111Effective concentration for the agonist in the isolated blood vessel using in vitro femoral artery1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Design, synthesis, and structure-activity relationships of a new series of alpha-adrenergic agonists: spiro[(1,3-diazacyclopent-1-ene)-5,2'-(1',2',3',4'- tetrahydronaphthalene)].
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (10.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]